Literature DB >> 17345041

APOE genotypes in Greek multiple sclerosis patients: no effect on the MS Severity Score.

Georgios Koutsis, Marios Panas, Georgia Karadima, Dimitris Mandellos, Constantinos Sfagos, Constantin Potagas, Demetris Vassilopoulos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17345041     DOI： 10.1007/s00415-006-0375-9

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  10 in total

1.  APOE genotype is a major predictor of long-term progression of disability in MS.

Authors:  J Chapman; S Vinokurov; A Achiron; D M Karussis; K Mitosek-Szewczyk; M Birnbaum; D M Michaelson; A D Korczyn
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

2.  No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis.

Authors:  J N P Zwemmer; T van Veen; L van Winsen; G J van Kamp; F Barkhof; C H Polman; B M J Uitdehaag
Journal:  Mult Scler       Date:  2004-06       Impact factor: 6.312

3.  Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis.

Authors:  F Fazekas; S Strasser-Fuchs; H Kollegger; T Berger; W Kristoferitsch; H Schmidt; C Enzinger; M Schiefermeier; C Schwarz; B Kornek; M Reindl; K Huber; R Grass; G Wimmer; K Vass; K H Pfeiffer; H P Hartung; R Schmidt
Journal:  Neurology       Date:  2001-09-11       Impact factor: 9.910

4.  Apolipoprotein E polymorphism in the Greek population.

Authors:  E Sklavounou; E Economou-Petersen; G Karadima; M Panas; D Avramopoulos; A Varsou; D Vassilopoulos; M B Petersen
Journal:  Clin Genet       Date:  1997-10       Impact factor: 4.438

5.  Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

Authors:  R H S R Roxburgh; S R Seaman; T Masterman; A E Hensiek; S J Sawcer; S Vukusic; I Achiti; C Confavreux; M Coustans; E le Page; G Edan; G V McDonnell; S Hawkins; M Trojano; M Liguori; E Cocco; M G Marrosu; F Tesser; M A Leone; A Weber; F Zipp; B Miterski; J T Epplen; A Oturai; P Soelberg Sørensen; E G Celius; N Téllez Lara; X Montalban; P Villoslada; A M Silva; M Marta; I Leite; B Dubois; J Rubio; H Butzkueven; T Kilpatrick; M P Mycko; K W Selmaj; M E Rio; M Sá; G Salemi; G Savettieri; J Hillert; D A S Compston
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

6.  Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis.

Authors:  S J Weatherby; C L Mann; M B Davies; D Carthy; A A Fryer; M D Boggild; C Young; R C Strange; W Ollier; C P Hawkins
Journal:  Mult Scler       Date:  2000-02       Impact factor: 6.312

7.  Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis.

Authors:  Silke Schmidt; Lisa F Barcellos; Karen DeSombre; Jacqueline B Rimmler; Robin R Lincoln; Patricia Bucher; Ann M Saunders; Eric Lai; Eden R Martin; Jeffery M Vance; Jorge R Oksenberg; Stephen L Hauser; Margaret A Pericak-Vance; Jonathan L Haines
Journal:  Am J Hum Genet       Date:  2002-02-11       Impact factor: 11.025

8.  Apolipoprotein E genotype does not influence the progression of multiple sclerosis.

Authors:  Giovanni Savettieri; Virginia Andreoli; Simona Bonavita; Rita Cittadella; Carlo Caltagirone; Maria Carolina Fazio; Paolo Girlanda; Francesco Le Pira; Maria Liguori; Giancarlo Logroscino; Alessandra Lugaresi; Ugo Nocentini; Arturo Reggio; Giuseppe Salemi; Paolo Serra; Gioacchino Tedeschi; Lucia Toma; Maria Trojano; Paola Valentino; Aldo Quattrone
Journal:  J Neurol       Date:  2003-09       Impact factor: 4.849

9.  Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin.

Authors:  Mónica Santos; Maria do Carmo Costa; Maria Edite Rio; Maria José Sá; Marta Monteiro; Angela Valença; Alfredo Sá; José Dinis; José Figueiredo; Luís Bigotte de Almeida; António Valongueiro; Isabel Coelho; Maria Teresa Matamá; Jorge Pinto-Basto; Jorge Sequeiros; Patrícia Maciel
Journal:  Mult Scler       Date:  2004-04       Impact factor: 6.312

Review 10.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422
  10 in total
  3 in total

Review 1.  Multiple sclerosis in the elderly patient.

Authors:  Amer Awad; Olaf Stüve
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

Review 2.  The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Hong-Liang Zhang; Jiang Wu; Jie Zhu
Journal:  Clin Dev Immunol       Date:  2010-05-31

Review 3.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.